J&J offers up to $300M for each diabetes drug in Evotec/Harvard portfolio – FierceBiotech

Johnson & Johnson ($JNJ) is buying into a novel academic-biotech collaboration built around a portfolio … a challenging field with huge potential for any newly approved products. “We have not only achieved our scientific goals of creating …